8 recruiting, 1 not yet recruiting. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Recruiting 8, Not yet recruiting 1 |
Follow REGN7508: new trials by email Literature Review of REGN7508 trials Research Report on REGN7508
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants Cenvacibart, Placebo - Secondary Stroke | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 6106 | 2026-11-20 | 2026-10-15 |
| Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) REGN7508, REGN9933, Placebo - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1908 | 2026-09-07 | 2026-09-29 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers REGN7508, Apixaban - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1600 | 2026-08-26 | 2026-11-05 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation REGN7508, Apixaban, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 15364 | 2026-08-10 | 2026-11-05 |
| Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease REGN7508, REGN9933, Placebo - Peripheral Artery Disease (PAD) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 7050 | 2026-07-10 | 2026-11-05 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable REGN7508, REGN9933, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2628 | 2026-04-03 | 2026-11-10 |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis REGN7508, Placebo - Cancer-Associated Thrombosis (CAT) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1120 | 2026-03-09 | 2026-11-05 |
| REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants REGN7508, Acetylsalicylic Acid (ASA), Placebo - Symptomatic Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2000 | 2025-11-24 | 2026-11-05 |
| REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults REGN7508, Apixaban, Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2000 | 2025-06-25 | 2026-11-06 |
Venous Thromboembolism (5) · Pulmonary Embolism (4) · Thrombosis (4) · Venous Thrombosis (3) · Atrial Fibrillation (2) · Hemorrhage (2) · Ischemic Stroke (2) · Neoplasms (2) · Stroke (2) · Peripheral Arterial Disease (1)
United States (7) · Japan (4) · Bulgaria (2) · Canada (2) · Georgia (2) · Romania (2) · Greece (1) · Hungary (1) · Latvia (1) · Lithuania (1) · Malaysia (1) · Moldova (1) · Poland (1) · South Korea (1) · Spain (1)
2025 (5)